Fibroblast growth factor (FGF21) protects mouse liver against d-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways

• Published in: Molecular and cellular biochemistry 2015-05, Vol.403 (1-2), p.287-299
• Main Authors: Yu, Yinhang, Bai, Fuliang, Liu, Yaonan, Yang, Yongbi, Yuan, Qingyan, Zou, Dehua, Qu, Susu, Tian, Guiyou, Song, Liying, Zhang, Tong, Li, Siming, Liu, YunYe, Wang, Wenfei, Ren, Guiping, Li, Deshan
• Format: Article
• Language: English
• Subjects: Animals; Antioxidants; Antioxidants - metabolism; Apoptosis; Apoptosis - drug effects; Biochemistry; Biomarkers - metabolism; Biomedical and Life Sciences; Cardiology; Caspase 3 - metabolism; Cell Nucleus - drug effects; Cell Nucleus - metabolism; Dextrose; Enzyme Activation - drug effects; Enzymes; Fibroblast growth factors; Fibroblast Growth Factors - pharmacology; Galactose; Genetic research; Glucose; Glucose metabolism; Hepatocytes - drug effects; Hepatocytes - metabolism; Life Sciences; Lipids; Liver; Liver - drug effects; Liver - enzymology; Liver - metabolism; Liver - pathology; Male; Medical Biochemistry; Mice; NF-E2-Related Factor 2 - metabolism; Oncology; Oxidative stress; Oxidative Stress - drug effects; Phosphatidylinositol 3-Kinases - metabolism; Physiological aspects; Protective Agents - pharmacology; Protein Transport - drug effects; Proto-Oncogene Proteins c-akt - metabolism; Reactive Oxygen Species - metabolism; Rodents; Signal Transduction - drug effects
• ISSN: 0300-8177; 1573-4919
• DOI: 10.1007/s11010-015-2358-6

FGF21 is recently discovered with pleiotropic effects on glucose and lipid metabolism. However, the potential protective effect of FGF21 against d -gal-induced injury in the liver has not been demonstrated. The aim of this study is to investigate the pathophysiological role of FGF21 on hepatic oxidative injury and apoptosis in mice induced by d -gal. The 3-month-old Kunming mice were subcutaneously injected with d -gal (180 mg kg −1  d −1 ) for 8 weeks and administered simultaneously with FGF21 (5 or 1 mg kg −1  d −1 ). Our results showed that the administration of FGF21 significantly alleviated histological lesion including structure damage, degeneration, and necrosis of hepatocytes induced by d -gal, and attenuated the elevation of liver injury markers, serum AST, and ALP in a dose-dependent manner. FGF21 treatment also suppressed d -gal-induced profound elevation of ROS production and oxidative stress, as evidenced by an increase of the MDA level and depletion of the intracellular GSH level in the liver, and restored the activities of antioxidant enzymes SOD, CAT, GSH-Px, and T-AOC. Moreover, FGF21 treatment increased the nuclear abundance of Nrf2 and subsequent up regulation of several antioxidant genes. Furthermore, a TUNEL assay showed that d -gal-induced apoptosis in the mouse liver was significantly inhibited by FGF21. The expression of caspase-3 was markedly inhibited by the treatment of FGF21 in the liver of d -gal-treated mice. The levels of PI3K and PBK/Akt were also largely enhanced, which in turn inactivated pro-apoptotic signaling events, restoring the balance between pro- and anti-apoptotic Bcl-2 and Bax proteins in the liver of d -gal-treated mice. In conclusion, these results suggest that FGF21 protects the mouse liver against d -gal-induced hepatocyte oxidative stress via enhancing Nrf2-mediated antioxidant capacity and apoptosis via activating PI3K/Akt pathway.